← All trials
NCT04319276
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2020
- Primary completion
- Jul 31, 2023
- Completion date
- Jul 31, 2024
- First posted
- Mar 24, 2020
- Last posted
- Mar 25, 2020
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical College of WisconsinLead sponsor
- Medical College of WisconsinOverall official - principal investigator
- Medical College of WisconsinReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.